~~Table~~UNITED ofSTATES SECURITIES ~~Contents~~AND EXCHANGE COMMISSION

~~UNITED~~Washington, ~~STATES~~D.C. ~~SECURITIES AND EXCHANGE COMMISSION~~20549

~~Washington,~~FORM ~~D.C. 20549~~8-K

~~Form 8-K~~Current Report

~~Current~~Pursuant ~~Report~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13~~Report ~~or 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported): ~~Act~~February 28, ~~of 1934~~2007

~~Date~~Adeza ofBiomedical ~~Report (Date of earliest event reported): May 4, 2006~~Corporation

~~Adeza~~(Exact ~~Biomedical~~name ~~Corporation~~ of registrant as specified in its charter)

~~(Exact name of registrant as specified in its charter)~~000-20703

~~000-20703~~ (Commission File Number)

Delaware		77-0054952
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation)


Delaware (State or other jurisdiction of incorporation)		77-0054952 (I.R.S. Employer Identification No.)

1240 Elko Drive
Sunnyvale, California 94089
(Address of principal executive offices, with zip code)

(408) 745-0975
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

oItem ~~Soliciting~~5.02. ~~material~~Departure ~~pursuant~~of toDirectors ~~Rule~~or ~~14a-12~~Certain ~~under~~Officers; ~~the~~Election ~~Exchange~~of ~~Act~~Directors; ~~(17~~Appointment ~~CFR~~of ~~240~~Certain Officers; Compensatory Arrangements of Certain Officers.~~14a-12)~~

o On ~~Pre-commencement~~February 28, ~~communications~~2007, ~~pursuant~~the toBoard ~~Rule~~of ~~14d-2~~Directors (bthe “Board”) ~~under~~of Adeza Biomedical Corporation (the ~~Exchange~~“Company”) ~~Act~~approved increases to the base salaries for the Company’s named executive officers (17as ~~CFR~~defined ~~240.14d~~in Item 402 of Regulation S-~~2(b~~K promulgated by the Securities and Exchange Commission)). The Compensation Committee of the Board determines the annual salary adjustments of the Company’s named executive officers by evaluating the competitive marketplace, the performance of the Company, the performance of each executive and the operational areas of the Company for which that executive is responsible, and the responsibilities assumed by that executive. Each of the named executive officers received a merit increase in base salary, retroactive to February 1, 2007. The base salaries for the named executive officers retroactive to February 1, 2007, are as set forth across from each such officer’s name below:

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


		Base Salary Retroactive
Name	Title	to February 1, 2007
Emory V. Anderson	President and Chief Executive Officer	$	402,251
Mark D. Fischer-Colbrie	SVP, Finance and Administration and Chief Financial Officer	$	280,027
Durlin E. Hickok	SVP, Medical Affairs	$	276,203
Marian E. Sacco	SVP, Sales and Marketing	$	280,399
Robert O. Hussa	Vice President, Research and Development	$	215,955

~~TABLE OF CONTENTS~~SIGNATURES

~~Item~~ Pursuant ~~2.02~~to ~~Results~~the requirements of ~~Operations~~the ~~and~~Securities ~~Financial~~Exchange ~~Condition~~Act ~~Item~~of ~~8.01~~1934, ~~Other~~the ~~Events~~registrant ~~Item~~has ~~9.01~~duly caused ~~Financial~~this ~~Statements~~report ~~and~~to ~~Exhibits~~be ~~SIGNATURES~~signed ~~EXHIBIT~~on ~~INDEX~~its ~~EXHIBIT~~behalf ~~99.1~~by ~~EXHIBIT~~the 99undersigned hereunto duly authorized.2


	ADEZA BIOMEDICAL CORPORATION
Date: March 6, 2007	By:	/s/ Mark D. Fischer-Colbrie
		Mark D. Fischer-Colbrie
		Chief Financial Officer

Item 2.02 Results of Operations and Financial Condition

On May 4, 2006 Adeza Biomedical Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2006. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 8.01 Other Events

On May 4, 2006, the Company issued a press release announcing the submission to the United States Food and Drug Administration of a new drug application for GestivaTM, its product candidate for the prevention of recurrent preterm birth. The press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

		Exhibit 99.1		Press release dated May 4, 2006
		Exhibit 99.2		Press release dated May 4, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADEZA BIOMEDICAL CORPORATION
Date: May 4, 2006	By:	/s/ Mark D. Fischer Colbrie
		Mark D. Fischer-Colbrie
		Vice President, Finance and Administration and Chief
		Financial Officer

EXHIBIT INDEX

Exhibit
number		Description
99.1		Press release dated May 4, 2006
99.2		Press release dated May 4, 2006

Table of Contents

Table of Contents

Table of Contents

Filing Compare · ADEZA BIOMEDICAL CORP